233 related articles for article (PubMed ID: 33398063)
1. Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy.
Broad RV; Jones SJ; Teske MC; Wastall LM; Hanby AM; Thorne JL; Hughes TA
Br J Cancer; 2021 Mar; 124(6):1110-1120. PubMed ID: 33398063
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
[TBL] [Abstract][Full Text] [Related]
3. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
4. Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
Kikuchi K; McNamara KM; Miki Y; Moon JY; Choi MH; Omata F; Sakurai M; Onodera Y; Rai Y; Ohi Y; Sagara Y; Miyashita M; Ishida T; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2017 Dec; 166(3):709-723. PubMed ID: 28831645
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of FGF9 and NOVA1 in cancer-associated fibroblasts promotes cell proliferation, invasion and migration of triple negative breast cancer.
Zhang B; Liu Y; Yu J; Lin X
Drug Dev Res; 2024 May; 85(3):e22185. PubMed ID: 38657094
[TBL] [Abstract][Full Text] [Related]
6. IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment.
Maia A; Gu Z; Koch A; Berdiel-Acer M; Will R; Schlesner M; Wiemann S
Mol Oncol; 2021 May; 15(5):1308-1329. PubMed ID: 33476079
[TBL] [Abstract][Full Text] [Related]
7. ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts.
Sung JS; Kang CW; Kang S; Jang Y; Chae YC; Kim BG; Cho NH
Oncogene; 2020 Jan; 39(3):664-676. PubMed ID: 31534187
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
9. Exploring the association of POSTN
Lin S; Zhou M; Cheng L; Shuai Z; Zhao M; Jie R; Wan Q; Peng F; Ding S
Int J Biol Macromol; 2024 May; 268(Pt 1):131560. PubMed ID: 38631570
[TBL] [Abstract][Full Text] [Related]
10. Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).
Rong G; Kang H; Wang Y; Hai T; Sun H
PLoS One; 2013; 8(8):e70960. PubMed ID: 23951052
[TBL] [Abstract][Full Text] [Related]
11. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
13. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs).
Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M
J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144
[TBL] [Abstract][Full Text] [Related]
14. Bruceine D suppresses CAF-promoted TNBC metastasis under TNF-α stimulation by inhibiting Notch1-Jagged1/NF-κB(p65) signaling.
Chen H; Han X; Zhang Y; Wang K; Liu D; Hu Z; Wang J
Phytomedicine; 2024 Jan; 123():154928. PubMed ID: 38043386
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblasts induce an aggressive phenotypic shift in non-malignant breast epithelial cells via interleukin-8 and S100A8.
Lim H; Koh M; Jin H; Bae M; Lee SY; Kim KM; Jung J; Kim HJ; Park SY; Kim HS; Moon WK; Hwang S; Cho NH; Moon A
J Cell Physiol; 2021 Oct; 236(10):7014-7032. PubMed ID: 33748944
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
17. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
Adinew GM; Messeha SS; Taka E; Badisa RB; Antonie LM; Soliman KFA
Nutrients; 2022 May; 14(10):. PubMed ID: 35631261
[TBL] [Abstract][Full Text] [Related]
18. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
[TBL] [Abstract][Full Text] [Related]
19. Cancer associated fibroblasts modulate the cytotoxicity of anti-cancer drugs in breast cancer: An in vitro study.
Kashyap D; Bhattacharya S; Irinike S; Khare S; Das A; Singh G; Bal A
Breast Dis; 2024; 43(1):25-36. PubMed ID: 38517765
[TBL] [Abstract][Full Text] [Related]
20. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
